Amit Kumar was appointed Chairman and CEO of Anixa Biosciences on August 20, 2025, coinciding with the CNIPA issuing a Notice of Allowance for a patent.
4 reports, 1 independent
Updated Jun 29
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amit Kumar was appointed Chairman and CEO of Anixa Biosciences on August 20, 2025, coinciding with the CNIPA issuing a Notice of Allowance for a patent.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Amit Kumar appointed Chairman/CEO of Anixa Biosciences; CNIPA granted patent allowance.1 source
Amit Kumar's company, Anixa Biosciences, announced a trial from its San Jose base.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- PR NewswireAnixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology Notice of Allowance marks first Chinese
- PR NewswireAnixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to D
- PR NewswireAnixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12,